The Voluntary Escrow serves further validates investors belief and support of Havn Life’s business plan and future growth strategy
VANCOUVER, BC / ACCESSWIRE / November 18, 2020 / Havn Life Sciences Inc. (CNSX:HAVN) (FRA:5NP) (OTC:HAVLF) (the “Company” or “Havn Life”), is pleased to announce that certain shareholders have entered into voluntary escrow agreements with the Company pursuant to which an aggregate 6,300,000 common shares will be subject to a contractual resale restriction until March 8, 2021 (the “Escrowed Shares“). The Escrowed Shares were originally subject to a four-month statutory hold period which will expire on January 8, 2021.
“Havn Life has always appreciated the support of its staff, management and shareholders. This voluntary escrow only confirms our major shareholders confidence and commitment to what we are building. I would like to personally thank our shareholders for sharing our belief in our vision and our Company’s future upside.” commented Tim Moore, CEO of the Company. “The team is continuing to diligently work towards reaching our goals and milestones over the coming 12 months.
On Behalf of The Board of Directors
Chief Executive Officer
About Havn Life Sciences Inc.
Havn Life Sciences is a biotechnology company on a mission to unlock human potential using evidence-informed research. The Company is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from non-regulated compounds. Learn more at: havnlife .com and follow us on Facebook, Twitter and Instagram.
Investor Relations: ir@havnlife .com 604 687 7130
Media: brittany@exvera .com 778 238 6096
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future of the Company’s business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release
SOURCE: Havn Life Sciences Inc.
View source version on accesswire.com: